Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury

J Med Chem. 2018 Mar 8;61(5):2041-2051. doi: 10.1021/acs.jmedchem.7b01806. Epub 2018 Feb 15.

Abstract

Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans. We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation. These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.

MeSH terms

  • Chemical and Drug Induced Liver Injury / etiology*
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / metabolism
  • Imidazoles / pharmacology*
  • Prostaglandin-E Synthases / antagonists & inhibitors*
  • Safety-Based Drug Withdrawals
  • Structure-Activity Relationship

Substances

  • Imidazoles
  • LY3031207
  • 2-aminoimidazole
  • imidazole
  • PTGES protein, human
  • Prostaglandin-E Synthases